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Several variants of CTLA-4 have been reported to be associated with susceptibility systemic lupus erythematosus (SLE); however,
ﬁndings have been inconsistent across diﬀerent populations. Using a case-control study design, we have investigated the role of
CTLA-4 polymorphism at positions −1661 and −1722 on SLE susceptibility in our Chinese SLE population in central China’s
Hubei province. Samples were collected from 148SLE patients and 170 healthy controls. Polymerase chain reaction restriction
fragments length polymorphism (PCR-RFLP) was used to analyze the genotypes of the two sites. Statistically signiﬁcant diﬀerence
was observed in genotypes for −1722, but not for −1661. The frequency of the T allele on the −1722 SNP was signiﬁcantly
increased in SLE patients: 57.8% versus 40.6% in controls (P<0.001, OR = 2.002). While the detected C allele frequency in the
controls was signiﬁcantly elevated in comparison to that in the SLE patients (59.4% versus 42.2%). On the contrary, no association
was found between SLE and CTLA-4 polymorphism at position −1661.
1.Introduction
Systemiclupuserythematosus(SLE)isachronicmultisystem
autoimmune disease and is considered to be caused by
complex interactions between genetic risk, environmental,
and hormonal factors that result in an immune dysreg-
ulation, and autoantibody production ensued [1–3]. Epi-
demiological studies reported that SLE is more common in
Asians(46.7/100000)thaninCaucasians(20.7/100000),and
ethnicity also inﬂuences the age of onset and severity of its
manifestations [4, 5].
The precise aetiopathogenesis of SLE is still unclear;
however, the search for genes and molecular interactions
that inﬂuence disease has promoted our understanding of
pathogenesis and genetic contributions to autoimmunity in
SLE [6]. Genetic association studies and recent advances in
the ﬁeld of single nucleotide polymorphisms (SNPs) have
been highly successful in identifying several loci associated
with disease susceptibility [7, 8].
The CTLA-4 molecule has a suppressive eﬀect on T-
cell activation and might contribute to maintain immune
tolerance by blocking CD28-dependent T cell activation
throughinteractionswithitsligandCD80/86onantigenpre-
senting cells [7]. The CTLA-4/B7 complex can compete with
the CD28/B7 complex and convey an inhibitory inﬂuence to
the T cell aﬀecting T cell development, cytokine production,
and immune reactions [8].
CTLA-4 would, therefore, be an important negative reg-
ulator of T-cell responses, and its dysregulation has the
potential to aﬀect the pathogenesis of SLE by altered
activation of T cells to self-antigens [9, 10]. The CTLA-4
gene is located within the risk region on chromosome 2q33,
and several polymorphisms have been reported in this gene.
However, only few of them have been studied for association
with SLE susceptibility, of which, two are located within the
promoter region: a T/C change at position −1722 and an
A/G transition at position −1661 [11–13]. The former could
alter transcription factor binding sites whereas the latter may
alter the potential response element for myocyte enhancer
factor 2 (MEF2) [14]. Hence, allelic variations of these two
sitesmightleadtoadiﬀerentialsusceptibilitytoSLEresulting
from unbalanced or ineﬃcient immune responses.2 Journal of Biomedicine and Biotechnology
Although CTLA-4 polymorphism has been shown to be
associated with a number of autoimmune diseases, including
SLE, Graves’ disease, multiple sclerosis, and type 1 diabetes,
the associations have not been always replicated in diﬀerent
populations [11, 12, 15]. Recent studies showed that the
CTLA-4 polymorphism plays an important role in SLE in
somepopulations,whichhasnotbeenconﬁrmedinChinese.
Using a case-control study design, we have investigated
the role of CTLA-4 polymorphism at positions −1661 and
−1722 on SLE susceptibility in our Chinese SLE population
in central China’s Hubei Province.
2. Patientsand Methods
2.1. Study Population. A total of 148 patients (17 males
and 131 females) meeting the 1997 revised criteria of the
American College of Rheumatology (ACR) for SLE [16]
were recruited from Renmin and Zhongnan Hospitals of
WuhanUniversity,Wuhan,China.Controlswere170healthy
volunteers with no history of autoimmune disease, collected
for a case-control study. All patients and controls were Han
Chinese residing in the central part of China. The study
was approved by the hospitals’ Ethics Committee of Wuhan
University, and all subjects were consented to participate in
the study.
2.2. DNA Extraction and Genotyping. DNA from patients
and controls was extracted from peripheral blood with
DNA ﬂash kit 2.0 (HaiGene Biotechnolgy Co., Ltd., Gentra
Systems Corp.) according to the standard protocol from
the manufacturer. The polymorphisms at positions −1661
and −1722 were analyzed by PCR-RFLP (polymerase chain
reaction-restriction fragments length polymorphism) [13],
using the speciﬁc oligonucleotide primers (Sangon, Shang-
hai, China), 5 CTAAGAGCATCCGCTTGCACCT3  and
5 TTGGTGTGATGCACAGAAGCCTTTT3 . PCR ampli-
ﬁcation conditions were carried out as follows: initial
denaturation at 94◦C for 5 minutes, then thirty cycles at
94◦C (15s), 60◦C (30s), 72◦C (45s), and one ﬁnal extension
at 72◦C for 8min. The products of the PCR were digested
with BvbIo rMseIa t3 7 ◦C for 4h, and then were analyzed
by 2% agarose gel electrophoresis stained with ethidium
bromide. After resolving, the −1722 T/C polymorphism was
determinedbydetectinga486bpdigestedfragment(Tallele)
or two fragments of 270 and 216bp (C allele); (Figure 1).
The −1661A/G polymorphism was determined by detecting
a 486bp fragment (G allele) or two fragments of 347 and
139bp (A allele); (Figure 2).
2.3. Statistical Analyses. We tested for Hardy-Weinberg
equilibrium (HWE) among cases and controls. Allelic and
genotypic frequencies were calculated by direct counting.
The chi-square test with Yates correction and Fisher exact
test were used to compare genotypes and alleles frequencies.
Statistical signiﬁcance was deﬁned as P<0.05. The odds
ratio (OR) was calculated to measure the strength of the
association observed.
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Figure 1: PCR restriction fragment length polymorphism results
of −1722 T to C substitution in CTLA-4 promoter region. (1) CC
genotype; (2) TT genotype; (3) TC genotype.
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Figure 2: PCR restriction fragment length polymorphism results
of −1661 A to G substitution in CTLA-4 promoter region.(1) AG
genotype; (2) AA genotype; (3) GG genotype.
3. Results and Discussion
The genotypic frequencies for the two sites tested were not
found to be deviated from those predicted from Hardy-
Weinberg equilibrium in both SLE patients and controls.
Genotype and allele frequencies of the −1722 T/C and
−1661 A/G polymorphisms are shown in Tables 1 and 2.
As observed, the genotypes at position −1722 were stronglyJournal of Biomedicine and Biotechnology 3
Table 1: Genotypic distribution and allelic frequencies of −1722 CTLA-4 polymorphisms in Chinese SLE patients and healthy controls.
Promoter −1722 SLE
n = 148
Controls
n = 170 x2 P value OR (95% CI)
Genotype frequency
TT 42 (28.4%) 29 (17.1%) 5.846 0.016 1.926 (1.127–3.293)
TC 87 (58.8%) 80 (47.1%) 4.362 0.037 1.605 (1.028–2.503)
CC 19 (12.8%) 61 (35.8%) 22.315 < 0.001 0.263 (0.148–0.468)
Allele frequency
T 171 (57.8%) 138 (40.6%) 18.701 < 0.001 2.002 (1.459–2.747)
C 125 (42.2%) 202 (59.4%)
Phenotype
T 129 (87.2%) 109 (64.1%) 6.182 0.013 1.574 (1.100–2.253)
C 106 (71.6%) 141 (82.9%)
Abbreviations: CTLA-4 = cytotoxic T-lymphocyte antigen 4; SLE =systemic lupus erythematosus; OR = odds ratios; 95% CI = 95% conﬁdence interval.
Table 2: Genotypic distribution and allelic frequencies of −1661 CTLA-4 polymorphisms in Chinese SLE patients and healthy controls.
Promoter −1661 SLE
n = 148
Controls
n = 170 x2 P-value OR (95% CI)
Genotype frequency
AA 59 (39.9%) 63 (37.1%) 0.263 0.608 1.126 (0.716–1.771)
AG 67 (45.2%) 76 (44.7%) 0.010 0.920 1.132 (0.730–1.755)
GG 22 (14.9%) 31 (18.2%) 0.647 0.421 0.783 (0.431–1.423)
Allele frequency
A 185 (62.5%) 202 (59.4%) 0.633 0.426 1.139 (0.827–1.568)
G 111 (37.5%) 138 (40.6%)
Phenotype
A 126 (85.1%) 139 (81.8%) 0.207 0.649 1.090 (0.752–1.578)
G 89 (60.1%) 107 (62.9%)
Abbreviations: CTLA-4 = cytotoxic T-lymphocyte antigen 4; SLE = systemic lupus erythematosus; OR = odds ratios; 95% CI = 95% conﬁdence interval.
associated with SLE. The frequency of the T allele on the
−1722 SNP was signiﬁcantly increased in SLE patients:
57.8% versus 40.6% in controls (P<0.001, OR = 2.002).
While the detected C allele frequency in the controls was
signiﬁcantly elevated in comparison with that in the SLE
patients (59.4% versus 42.2% ). The frequencies of T/T
homozygotes and T/C heterozygotes were also signiﬁcantly
higher in patients than in controls (28.4% versus 17.1%,
P = 0.016,OR=1.926;58.8%versus47.1%,P = 0.037,OR=
1.605). Conversely, the frequencies of C/C homozygotes was
considerably higher in controls than in patients (35.8%
versus 12.8%, P<0.01, OR = 0.263). We observed no
signiﬁcant diﬀerence in the distribution of the alleles and
genotypes for the −1661 site between patients and healthy
subjects.
Notwithstanding the convincing evidence that CTLA-4
polymorphism plays an important role in susceptibility
to SLE, contradictory result has been reported among
diﬀerent populations [12] .S e v e r a ls t u d i e sh a v eo b s e r v e d
a signiﬁcant association of SLE with CTLA-4 gene poly-
morphisms [12, 13, 17–19]. While on the contrary, other
studies showed a lack of association with that genetic
variation [20–22]. Reasons for the variability in associations
are still ambiguous. Thus, investigating the frequencies and
distribution of variants CTLA-4 gene across populations are
essential for understanding disease association and discovery
of population diﬀerences, especially for Chinese as they
have a much higher SLE prevalence than the Europeans
[4, 5]. The interval encompassing the CTLA-4 locus on
chromosome 2q33 has been reported to show linkage to SLE
in two genome-wide association studies (GWAS) [23, 24].
Av e r yr e c e n tG W A Sh a sc o n ﬁ r m e dt h a tv a r i a t i o ni nt h e
CTLA-4 gene has been associated with a genetic risk of
SLE [25]. Although, this polymorphism may has not yet
reached stringent thresholds of lupus GWAS performed in
some Chinese cohorts, however, the association has been
observed in multiple independent studies in various ethnic
populations including Asian [12, 13, 17–19, 23–26], and
there is strong biological evidence suﬃcient to conclude
that CTLA-4 polymorphism confers susceptibility to SLE
through its crucial functions in T cell activation/regulation
[11, 24, 25, 27–30].
Recently, a GWAS study conﬁrmed an SLE susceptibility
locus at chromosome 2q32.3 in Chinese population that is
near the region 2q33 which encodes the genes for CTLA-4
[31]. As polymorphisms that are near each other have4 Journal of Biomedicine and Biotechnology
a tendency to be inherited together, something worth further
pursuit in future studies. In Asian people, positive associa-
tions of the CTLA-4 polymorphism with SLE were reported
in Korean [13] and Japanese [17] while no such association
was found in Malaysian population [32]. Signiﬁcantly, a
meta-analysis by Lee et al. found a close association between
S L Ea n de x o n1a t+ 4 9o fCTLA-4 gene, especially in Asians
[12]. Liu et al. did not observe an association of CTLA-4
polymorphism with SLE in Taiwanese, but suggested that it
is possible that this polymorphism could aﬀect some speciﬁc
clinical features [20]. This discrepancy with the ﬁndings of
thecurrentstudymaybepartiallyattributedtothevariations
among Chinese living in diﬀerent geographical regions [33].
The results of this study conﬁrm the involvement of
CTLA-4 polymorphisms at the promoter −1722 on SLE
susceptibility in the Chinese population. Our ﬁndings are in
agreement with the results of other ethnic groups demon-
strating the inﬂuence of this polymorphism in the suscep-
tibility to SLE. On the contrary, the genotypic frequencies
for the −1661 site were not found to be signiﬁcantly
diﬀerent between patients and controls. Other studies on
−1661 polymorphism in Korean with SLE also could not
ﬁnd a positive correlation [13]. In addition, no overall
associations were seen between this polymorphism and
SLE in African-Americans [22]. Being inexplicit, despite
the short distance between the two locations, only −1722
Promoter region polymorphisms was associated with SLE,
while the other −1661 is not. This possibly due to some
functional diﬀerences between the two sites on regulatory
properties of this promoter might aﬀect basal promoter
activity and gene expression. Polymorphisms in promoter
regions may aﬀect the gene expression quantitatively or
qualitatively by altering transcription factor binding sites or
other controlling domains [34].
The signiﬁcant increase in the C allele observed in the
controls is assumed to play a protective role against SLE in
Chinese. On the other hand, The T/T and T/C genotypes
of −1722 T/C polymorphisms were associated with higher
risk to have SLE. Hudson et al. [13] studied CTLA-4
polymorphisms at positions T/C −1722 in Korean popu-
lation and found that T allele was more frequent in SLE
patients while C allele was decreased in the controls and
suggested that the C allele could contribute protectively to
SLEintheKoreanpopulation.Incontrast,Fernandez-Blanco
et al. [18] found that the C allele of the −1722 T/C SNP
was associated with SLE susceptibility in the Spanish SLE
patients. However, another study did not ﬁnd any signiﬁcant
associationbetweenthegeneticpolymorphismsatthe −1722
T/C SNP of the CTLA-4 gene and Spanish SLE patients
[21]. Although there were signiﬁcant associations in two
of the three studies described above. However, a published
meta-analysis study did not unveil a signiﬁcantly increased
odds ratio for this polymorphism [12]. Takeuchi et al. also
reported a slight increase in the allele frequency of −1722 C
in Japanese patients with SLE compared to the controls, but
the diﬀerence was not statistically signiﬁcant [35].
Because there are relatively few studies, it is diﬃcult to
explain the contradictories at the promoter −1722 polymor-
phism in SLE, but they may be due to a diﬀerent genetic
background and a possible role for racial and ethnic inﬂu-
ences in the pattern of haplotypes on the CTLA-4 locus
between various populations in SLE predisposition [4, 5].
Variations in associations among populations may be also
related to diﬀerence in patient characteristics or the distri-
bution of other risk factors that interact with CTLA-4 con-
cerningSLE.Moreover,geneticevidencesuggeststhatgenetic
heterogeneity, a common phenomenon in complex diseases,
are responsible for a considerable portion of this variability
[36].WebelievethatthereisnotsuﬃcientresearchonCTLA-
4 polymorphisms to identify and demonstrate the role of
these important genetic variants that confer susceptibility to
SLE susceptibility among diﬀerent populations.
Whereas some polymorphisms on the CTLA-4 gene have
been analyzed in various populations for investigating an
association with SLE, only one of these, the CTLA-4 A/G
polymorphism at position +49 in exon 1, has been widely
studied, mainly in European populations [12]. Accordingly,
weexpectthattheresultsofourstudytoreinforcetheinterest
of focusing on analyzing the role of CTLA-4 polymorphism
in increased susceptibility to SLE. Furthermore, an elevated
level of soluble CTLA-4 in sera has been described in SLE,
with a positive and signiﬁcant correlation between plasma
sCTLA-4 concentration and SLE activity [28, 29]. Besides,
the therapeutic use of CTLA4Ig which is a soluble fusion
protein that interferes with T cell activation by inhibiting
the B7/CD28 costimulatory interaction, appears to delay or
extenuate disease development in experimental models of
lupus [37]. In this way, the results observed should provide
new postulates for the immunological role of this costim-
ulatory molecule in the pathogenesis of SLE and should
facilitate recent advances in the exploration of therapeutic
agents targeting T-cell activation in this disease [29].
Other polymorphisms have also been described in the
promoter region (−658 and −318), the CT60 (A/G), and at
the 3-end of the gene as well as the microsatellite (AT)(n)
in the 3 -untranslated region (3 -UTR) of the CTLA-4 gene.
Nevertheless, the reported results have been inconsistent
across diﬀerent ethnic populations [12, 38]. Hence, further
explorations of these polymorphisms are needed in order to
more fully examine SLE associations with CTLA-4 locus in
Chinese population. Allelic and genotypic frequencies may
vary between the populations; therefore, disease association
studies and interpreting their results oﬀer a possible route
to understanding the inﬂuence of these genetic variants on
disease aetiology and potentially to the development of new
treatments.
4. Conclusions
CTLA-4 polymorphism at positions −1722 was signiﬁcantly
associated with SLE and may be a risk factor for SLE
susceptibility in Chinese. Our results concur with the major-
ity of those published supporting the important inﬂuence
of CTLA-4 polymorphisms in the susceptibility to SLE.
Nevertheless,furtherstudyintermsofthefunctionalanalysis
ofpolymorphismsontheCTLA-4geneneedstobedone,and
largerpopulationstudiesindiﬀerentethnicgroupsshouldbe
performed in the future.Journal of Biomedicine and Biotechnology 5
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